Heranba Industries Ltd

- There is no specific mention of any planned fundraising through debt or equity in the current or future period. - The company plans to fund its CAPEX of around ₹250 crore over the next two to three years mostly through internal accruals. - They have good internal accruals currently and expect to use surplus cash generated for investments, registrations, new geographies, and new products. - Management is open to inorganic acquisitions if good synergistic opportunities arise, supported by strong capital accruals. - No explicit intention to raise external debt or equity was indicated during the discussion.

- Heranba Industries plans CAPEX of around ₹250-270 crores over the next 2-3 years, mainly funded through internal accruals. - Approximately 70% of this CAPEX is directed toward capacity expansion for new products, with the remaining 30% for existing products. - New technical capacity addition expected in phases, potentially adding 5,000 to 10,000 metric tons. - A new technical manufacturing site is planned to start operations by Q3 (September-October). - The company aims to leverage surplus cash generated (estimated ₹600-650 crores operating cash flow over FY22-FY24) for new investments including registrations, new geographies, and product launches. - Management is open to inorganic growth and acquisitions if synergistic opportunities arise. - R&D plans include 4-5 new products launches each in FY23 and FY24, with additional pipeline development ongoing.

- The company targets a revenue growth CAGR of 18% to 20% over the next 3 to 5 years. - They expect exports to increase to about 60% of total sales, with domestic sales around 40%. - Capacity expansion of around INR 250-270 crores over 2-3 years aims to add approximately INR 1,000 crores in revenue. - Current capacity utilization is about 90% for technicals and 55% for formulations, expected to rise with new registrations. - New product launches include 4-5 products planned for FY23 and similar numbers for FY24, focusing on herbicides, fungicides, and insecticides. - The product pipeline aims for $600-$700 million opportunity size in US, Europe, and LATAM markets. - Management targets sustaining or improving EBITDA margins around 18-19%. - Growth driven by both volume and value increases, supported by internal accruals and potential inorganic opportunities.

- The company expects revenue growth at a CAGR of 18% to 20% over the next 3 to 5 years. - EBITDA margins are expected to be maintained around 18% to 19%, with potential for improvement due to new product launches. - Gross margins are anticipated to be stable around 35% to 36% on a full-year basis. - Earnings per share (EPS) showed a strong 61.75% increase y-o-y recently, indicating robust profit growth. - Operating profits increased significantly in FY21 and are expected to sustain with new registrations and geographical expansion. - New product launches, especially in technicals and formulations, as well as expansion in exports to US, Europe, and LATAM, will drive growth. - Capital expenditure of about ₹250-270 crores over 2-3 years aims at capacity expansion and new product development, funded mainly through internal accruals. - Management remains open to inorganic growth opportunities to utilize surplus cash post-capex.

- The transcript does not provide explicit details on the current or expected order book or specific pending orders in terms of volume or value. - It is mentioned that demand is strong, but exports are slightly delayed due to logistical challenges like container scarcity, causing slower movement rather than lost demand. - The company has orders in place for both domestic and export markets, with domestic growth noted as strong (90% growth) and export orders pending but with slow dispatch due to logistics. - The company has ongoing registrations and product launches planned, indicating a healthy future demand pipeline. - New product launches and capacity expansions suggest expectations for increasing order inflow in the coming years. Therefore, while no precise order book figures are provided, the company indicates a robust demand environment with some export shipment delays affecting order fulfillment timing.